Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Boston Medical Center, Boston University School of Medicine, Boston, MA (Dr Holland, Ms Young, and Dr Saia).
Department of Epidemiology, Boston University School of Public Health, Boston, MA; Scientific Research and Strategy, Aetion, Inc, Boston, MA (Mses Gibbs and Guang).
Am J Obstet Gynecol MFM. 2023 Aug;5(8):101025. doi: 10.1016/j.ajogmf.2023.101025. Epub 2023 May 19.
Management of patients with opioid use disorder during the acute postpartum period remains clinically challenging as obstetricians aim to mitigate postdelivery pain while optimizing recovery support.
This study aimed to evaluate postpartum opioid consumption and opioids prescribed at discharge among patients with opioid use disorder treated with methadone, buprenorphine, and no medication for opioid use disorder, as compared with opioid-naïve counterparts.
We conducted a retrospective cohort study of pregnant patients who underwent delivery at >20 weeks' gestation at a tertiary academic hospital between May 2014 and April 2020. The primary outcome of this analysis was the mean daily quantity of oral opioids consumed after delivery while inpatient, in milligrams of morphine equivalents. Secondary outcomes included the following: (1) quantity of oral opioids prescribed at discharge, and (2) prescription for oral opioids in the 6 weeks after hospital discharge. Multiple linear regression was used to compare differences in the primary outcome.
A total of 16,140 pregnancies were included. Patients with opioid use disorder (n=553) consumed 14 milligrams of morphine equivalents per day greater quantities of opioids postpartum than opioid-naïve women (n=15,587), (95% confidence interval, 11-17). Patients with opioid use disorder undergoing cesarean delivery consumed 30 milligrams of morphine equivalents per day greater quantities of opioids than opioid-naïve counterparts (95% confidence interval, 26-35). Among patients who underwent vaginal delivery, there was no difference in opioid consumption among patients with and without opioid use disorder. Compared with patients prescribed methadone, patients prescribed buprenorphine, and those prescribed no medication for opioid use disorder consumed similar opioid quantities postpartum following both vaginal and cesarean delivery. Among patients undergoing cesarean delivery, opioid-naïve patients were more likely to receive a discharge prescription for opioids than patients with opioid use disorder (77% vs 68%; P=.002), despite lower pain scores and less inhospital opioid consumption.
Patients with opioid use disorder, regardless of treatment with methadone, buprenorphine, or no medication for opioid use disorder consumed significantly greater quantities of opioids after cesarean delivery but received fewer opioid prescriptions at discharge.
在急性产后期间,管理阿片类药物使用障碍患者仍然具有临床挑战性,因为产科医生旨在减轻分娩后的疼痛,同时优化康复支持。
本研究旨在评估接受美沙酮、丁丙诺啡和未接受阿片类药物使用障碍治疗的患者与阿片类药物未使用的患者相比,在接受治疗的阿片类药物使用障碍患者中,产后阿片类药物的消耗量和出院时开的阿片类药物。
我们对 2014 年 5 月至 2020 年 4 月在一家三级学术医院接受 >20 周妊娠分娩的孕妇进行了回顾性队列研究。本分析的主要结果是住院期间每天口服阿片类药物的平均剂量,以吗啡当量毫克表示。次要结果包括:(1)出院时开的口服阿片类药物的数量,以及(2)出院后 6 周内开的口服阿片类药物的处方。使用多元线性回归比较主要结果的差异。
共纳入 16140 例妊娠。与阿片类药物未使用的女性(n=15587)相比,阿片类药物使用障碍患者(n=553)产后每天多消耗 14 毫克吗啡当量的阿片类药物(95%置信区间,11-17)。行剖宫产的阿片类药物使用障碍患者每天多消耗 30 毫克吗啡当量的阿片类药物,而阿片类药物未使用的患者则多消耗 30 毫克吗啡当量(95%置信区间,26-35)。在接受阴道分娩的患者中,阿片类药物使用障碍患者与阿片类药物未使用患者之间的阿片类药物消耗量无差异。与接受美沙酮治疗的患者相比,接受丁丙诺啡治疗的患者和未接受阿片类药物使用障碍治疗的患者在阴道分娩和剖宫产分娩后都使用了类似剂量的阿片类药物。在接受剖宫产的患者中,尽管疼痛评分较低且住院期间阿片类药物消耗量较少,但阿片类药物未使用的患者比阿片类药物使用障碍患者更有可能获得出院阿片类药物处方(77% vs 68%;P=.002)。
无论接受美沙酮、丁丙诺啡还是未接受阿片类药物使用障碍治疗,阿片类药物使用障碍患者在剖宫产手术后都消耗了更多的阿片类药物,但出院时的阿片类药物处方却更少。